LJC has received honoraria from Amgen, Bristol Myers Squibb, Celgene, Janssen, Karyopharm Therapeutics, and Sanofi; has been in a consulting or advisory role with AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, Janssen, and Karyopharm Therapeutics; has received research funding from Amgen, Bristol Myers Squibb, Celgene, Janssen and Juno; and has been in Speakers' Bureau role for Amgen and Sanofi. TWL has received honoraria from Agilix Health and Lilly; has been in a consulting or advisory role with AbbVie/Genentech, Agios/Servier, Astellas Pharma, BeiGene, Blue Note Therapeutics, Bristol Myers Squibb/Celgene, Flatiron Health, GSK, Novartis, and Pfizer; reports institutional funding from Bristol Myers Squibb and Jazz Pharmaceuticals; and has received fees for travel, accommodations, and expenses from AbbVie/Genentech, Agios, Bristol Myers Squibb/Celgene, and Incyte. HT has received honoraria from Amgen, AstraZeneca, Lilly, Novartis, Pfizer, Roche Pharma AG, and Vifor Pharma; has been in a consulting or advisory role with AstraZeneca, Daiichi Sankyo Pharmaceutical, Exact Sciences, GSK, Lilly, Novartis, Pfizer, Roche Pharma AG, and Seagen. PS has been in a consulting or advisory role with Amgen, CARsgen Therapeutics, Celgene, Janssen, and Karyopharm Therapeutics; and reports institutional funding from Amgen, Bristol Myers Squibb, Janssen, and Skyline Diagnostics. RPK and LS are employees at Statlog. PH, AM, JR, AS, DA, GN and MDD are employees at and hold stock ownership in Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.